HIV INTEGRASE INHIBITORS: THE BASIS OF EFFECTIVE AND SAFE ANTIRETROVIRAL THERAPY

Abstract

The article examines the efficacy and safety of HIV integrase inhibitors (raltegravir, dolutegravir) in antiretroviral therapy (ART) regimens in various groups of HIV-infected patients: patients with high HIV RNA blood levels, patients with low CD4-lymphocytes blood count, pregnant women, patients with tuberculosis or chronic hepatitis C, and patients in later years and /or with high cardiovascular risk, neurocognitive disorders. Particular attention is paid to the minimal risk of developing delayed ART complications in using raltegravir in ART regimens and combining raltegravir and drugs of various classes.